BBIO BridgeBio Pharma, Inc.: Company Short-Term Debts

Public company logo of BridgeBio Pharma, Inc. (BBIO)

High R&D costs and stringent FDA oversight create barriers that BridgeBio Pharma, Inc. (BBIO) overcomes through a narrow specialization in targeted therapy. Financial debt with a maturity of up to 12 months allows for a liquidity assessment, with the current mark equal to 0.00. The company acts as a scientific incubator, rapidly converting complex genetic research into accessible medical drugs.

BBIO (BridgeBio) Company Short-Term Debts history from 07/04/2022 to 10/29/2026

Metric breakdowns and analytics for BridgeBio Corp (BBIO)

- stock price and consensus target price:
Stock Price BridgeBio|BBIO - Consensus Target
- company stock capitalization data:
Market Capitalization BridgeBio Pharma|BBIO - Company Buyout Price
- business book valuation details:
Book Value per Share BridgeBio|BBIO - Book Capitalization|Market Value to Book Value Ratio bridgebio.com|BBIO - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital BridgeBio Pharma, Inc.|BBIO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio BridgeBio Pharma, Inc.|BBIO - Company Aggregate Indebtedness|Debts to Book Capitalization BridgeBio Pharma|BBIO - Long-Term Debt|Company Short-Term Debts BridgeBio|Quick Liquidity Indicator bridgebio.com
- net income and valuation multiples indicators:
BBIO - Final Profit
Summary company analysis:BridgeBio (BBIO)
Manufactured products of bridgebio.com

Short-term debt reflects the total obligations of the issuer with a maturity of up to one year. The current amount of short-term financial debt for BridgeBio Pharma, Inc. (BBIO) stands at 0.00, which determines the company's operational liquidity. The trend of this indicator is based on financial reporting data and captures the frequency of debt refinancing. For BridgeBio Pharma, Inc. (BBIO), such fluctuations are smoothed out by strong pricing power in the gene therapy segment. Inelastic demand for unique drugs ensures a stable cash flow to service these obligations.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts BGM Group Corp|Company Short-Term Debt Cogent Biosciences, Inc. (COGT)|Company Short-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Short-Term Debts KROS (Keros Pharma)|Short-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Current Liabilities|Current Liabilities KMDA|FULC: Company Short-Term Debts|Short-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Short-Term Debts|Company Short-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Current Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Rein Therapeutics RNTX|GELS (Gelteq Ltd) - Current Liabilities|Aytu Therapeutics - Company Short-Term Debts|Company Short-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)